List of Excipients in Branded Drug DULERA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	DULERA	mometasone furoate and formoterol fumarate dihydrate	0085-7206	ALCOHOL	1969-12-31
Merck Sharp & Dohme Corp	DULERA	mometasone furoate and formoterol fumarate dihydrate	0085-7206	OLEIC ACID	1969-12-31
Organon LLC	DULERA	mometasone furoate and formoterol fumarate dihydrate	78206-127	ALCOHOL	1969-12-31
Organon LLC	DULERA	mometasone furoate and formoterol fumarate dihydrate	78206-127	OLEIC ACID	1969-12-31

DULERA Excipient Strategy and Commercial Opportunities

Last updated: August 1, 2026

DULERA is a pressurized metered-dose inhaler containing mometasone furoate and formoterol fumarate dihydrate. Its excipient system is limited to HFA-227ea propellant, ethanol, and oleic acid. The narrow formulation creates a relatively clear generic-development target, but commercial success depends on device equivalence, plume and particle-size performance, formulation stability, and regulatory protection rather than on excipient substitution alone.[1]

The strongest opportunities are generic DULERA development, lower-environmental-impact propellant reformulation, device-compatible excipient optimization, and differentiated inhaled corticosteroid/long-acting beta agonist products. The principal barriers are complex inhalation bioequivalence requirements, combination-product manufacturing, residual formulation and method-of-use patents, and the need to demonstrate consistent lung delivery.

What excipients are used in DULERA?

The DULERA formulation uses three inactive components:

Component	Function	Commercial relevance
HFA-227ea, also called 1,1,1,2,3,3,3-heptafluoropropane	Propellant	Controls vapor pressure, aerosolization, plume velocity, and dose delivery
Ethanol	Cosolvent	Supports drug solubilization and influences evaporation, particle formation, and spray characteristics
Oleic acid	Surfactant or formulation stabilizer	Helps control suspension behavior, valve performance, drug dispersion, and aggregation
Canister, valve and actuator components	Device system rather than excipients	Determine emitted dose, spray pattern, plume geometry, particle-size distribution, and usability

DULERA is supplied in 100 mcg/5 mcg and 200 mcg/5 mcg strengths. Each actuation delivers mometasone furoate and formoterol fumarate, with the product generally administered as two inhalations twice daily.[1]

The formulation is not a simple liquid solution. The active ingredients are delivered through a pressurized aerosol system in which excipient composition and device engineering jointly determine lung deposition.

How does HFA-227ea affect DULERA performance?

HFA-227ea is the main propellant and has a direct effect on:

• Canister pressure
• Valve metering
• Spray velocity
• Plume geometry
• Evaporation rate
• Aerodynamic particle-size distribution
• Residual drug retention in the canister and actuator

A change in propellant concentration can alter emitted dose and fine-particle mass even when the nominal drug concentration remains unchanged. Generic developers therefore cannot assume that a formulation with the same active ingredients and label strengths will perform equivalently.

HFA-227ea also has a high global-warming potential relative to newer hydrofluoroolefin propellants. This creates a long-term reformulation opportunity, although a propellant change would require substantial device, stability, dose-delivery, and clinical or comparative-performance work.

What is the role of ethanol and oleic acid?

Ethanol affects the solubility and dispersion behavior of mometasone furoate and formoterol fumarate. It also changes the evaporation profile after actuation. That can influence the residual particle size reaching the respiratory tract.

Oleic acid is used to improve formulation behavior and reduce problems associated with drug aggregation and valve deposition. Its concentration can affect suspension uniformity, settling, redispersibility, actuator fouling, and emitted-dose consistency.

The excipient system therefore has a functional relationship with:

• Drug particle morphology
• Micronization
• Canister fill weight
• Valve metering volume
• Actuator orifice diameter
• Priming and repriming requirements
• Storage orientation
• Shake instructions
• Moisture exposure
• Extractables and leachables

What formulation patents protect DULERA?

DULERA protection is likely distributed across several patent categories rather than a single excipient patent. The commercially relevant categories are:

Patent category	Potential subject matter	Generic-development impact
Combination composition	Mometasone furoate combined with formoterol fumarate	Can create Paragraph IV exposure
Inhaled dosage form	Aerosol suspension or solution containing both active ingredients	May require a non-infringing formulation design
Drug ratio and strength	Specific corticosteroid/LABA ratios and dose ranges	May affect both strengths
Device and delivery system	Canister, valve, actuator and metering configuration	Can require a different device or design-around
Method of treatment	Asthma or maintenance-treatment regimens	Risk depends on labeling and proposed indication
Manufacturing process	Micronization, blending, filling or suspension-processing steps	Can affect contract-manufacturing and supply-chain choices
Regulatory exclusivity	NDA-related exclusivity or pediatric exclusivity	Can delay approval independently of patent expiry

The Orange Book, not the package insert, determines which patents are formally listed against the approved NDA. A current diligence review should map every listed patent to the 100/5 mcg and 200/5 mcg strengths, the approved indications, and the proposed generic labeling.[2]

Because DULERA combines two previously known respiratory actives, the remaining commercial risk is more likely to be concentrated in combination-formulation, device, method-of-use and manufacturing claims than in a conventional new-chemical-entity patent.

When does DULERA lose exclusivity?

DULERA received FDA approval in 2010. Its initial regulatory exclusivity period has expired. The current entry question is therefore driven primarily by patent listings, litigation outcomes, pediatric extensions, and the timing of FDA approval for abbreviated applications.[1][2]

Exclusivity element	DULERA relevance
New chemical entity exclusivity	Not the primary protection because both active ingredients were previously known
Three-year clinical-investigation exclusivity	Historical relevance; no longer the central barrier
Pediatric exclusivity	Must be checked against current FDA records and any applicable extension
Orange Book patents	Primary legal screening point for ANDA applicants
Regulatory review	Depends on ANDA completeness, product-specific guidance and FDA inspection
Device equivalence	A practical barrier even when patent risk is manageable

A generic applicant may file a Paragraph IV certification against listed patents. That filing can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and court developments.[3]

Which companies are challenging DULERA?

The relevant competitive group includes:

1. Generic pharmaceutical companies developing mometasone/formoterol pMDIs.
2. Inhalation-specialty companies with established canister, valve and actuator platforms.
3. Contract manufacturers with HFA filling and suspension-processing capacity.
4. Device companies developing lower-emission or alternative-propellant inhalers.
5. Companies pursuing dry-powder or soft-mist alternatives to the DULERA delivery format.

A company can compete without duplicating the DULERA pMDI formulation. Alternative commercial paths include:

• A generic pMDI with equivalent active ingredients and a different excipient ratio
• A dry-powder inhaler containing mometasone and formoterol
• A nebulized combination product
• A once-daily inhaled corticosteroid/LABA product
• A lower-carbon propellant platform
• A device-led product with dose counters, feedback mechanisms or digital adherence tools

The pMDI route is the closest substitution strategy. Alternative inhalers have greater differentiation potential but face new clinical, regulatory and commercial requirements.

What is the FDA regulatory status of DULERA?

DULERA is an FDA-approved fixed-dose inhaled combination for asthma maintenance treatment in patients aged five years and older, subject to the approved labeling.[1]

A generic applicant would generally pursue an ANDA. FDA review of an orally inhaled combination product can require evidence addressing:

• Pharmaceutical equivalence
• Device sameness or permitted device differences
• Comparative qualitative and quantitative formulation characteristics
• Delivered-dose uniformity
• Aerodynamic particle-size distribution
• Spray pattern and plume geometry
• Priming and repriming
• Single-actuation content
• Stability under labeled storage conditions
• In vitro performance
• Pharmacokinetic or pharmacodynamic equivalence where required
• Comparative clinical endpoint evidence where in vitro and systemic approaches are insufficient

FDA guidance for orally inhaled and nasal drug products places substantial weight on product performance rather than merely matching the inactive-ingredient list.[4]

What formulation strategy is most attractive for a generic DULERA product?

The lowest-risk strategy is a close Q1/Q2 formulation using the same excipient classes and a device platform capable of matching DULERA’s emitted-dose and aerosol-performance profile.

Strategy 1: Close excipient match

This approach maintains HFA-227ea, ethanol and oleic acid while optimizing:

• Concentration and suspension stability
• Drug particle-size distribution
• Oleic-acid level
• Fill weight
• Valve metering
• Actuator dimensions

It offers the strongest regulatory comparability but may leave the developer exposed to formulation or device claims.

Strategy 2: Excipient-ratio design-around

A developer may alter ethanol or oleic-acid concentration while preserving aerosol performance. The benefit is potential patent avoidance. The cost is a higher risk of failed emitted-dose, particle-size, stability or valve-deposition studies.

This strategy is attractive only when the patent claims are concentration-specific or otherwise narrow.

Strategy 3: Alternative propellant

Replacing HFA-227ea with a lower-global-warming-potential propellant could create a differentiated product. The opportunity includes:

• Environmental procurement advantages
• Future regulatory positioning
• Potential lifecycle-management rights
• New device-platform partnerships

The technical burden is high. Propellant substitution can alter vapor pressure, density, solubility, spray force, evaporation, particle formation and container compatibility. It is better suited to a branded lifecycle product or platform investment than to the lowest-cost first generic.

Strategy 4: Alternative inhaler format

A dry-powder or soft-mist formulation can avoid direct replication of the DULERA pMDI system. It may also improve usability for patients who have difficulty coordinating actuation and inhalation.

This path has weaker substitution economics because the product may not qualify as a straightforward generic equivalent. It may require a new drug application, hybrid pathway or additional clinical development.

What manufacturing and intellectual-property barriers affect DULERA?

Manufacturing barriers are concentrated in aerosol filling and suspension control. Key process controls include:

• Micronized active-ingredient handling
• Uniform blending without agglomeration
• Controlled ethanol and oleic-acid addition
• Low-moisture processing
• Crimping and valve integrity
• Accurate metered filling
• Canister pressure control
• Actuator and mouthpiece dimensional control
• Cleaning and particulate control
• Long-term stability testing

The active ingredients can have different density, surface-energy and dispersion characteristics. A formulation that passes initial assay testing may still fail dose uniformity or fine-particle-mass testing after storage.

Intellectual-property risk may also extend to:

• Suspension stabilization
• Specific aerosol compositions
• Canister-valve configurations
• Dose-counter integration
• Manufacturing sequences
• Use of the product in defined patient populations
• Combination therapy and treatment-duration claims

Freedom-to-operate analysis should separate formulation claims from device claims. A formulation design-around does not eliminate infringement risk if the actuator, valve or method-of-use claims remain relevant.

How strong is the DULERA patent estate?

The estate should be viewed as commercially meaningful but not equivalent to the protection surrounding a recently approved innovative medicine.

Factor	Assessment
Active ingredients	Mature molecules with extensive prior art
Combination product	Potentially more defensible than either active alone
Excipient system	Technically important, but often vulnerable to design-around
Device	Can create practical entry barriers
Method of use	Relevant if generic labeling includes protected use
Manufacturing	Can protect process know-how and supply reliability
Regulatory exclusivity	Limited compared with a new molecular entity
Litigation exposure	Concentrated around Orange Book-listed claims and Paragraph IV filings

Patent strength depends on claim construction, prosecution history, prior art, validity challenges and the precise generic formulation. A broad claim covering the active combination may be vulnerable to prior-art arguments, while a narrower claim directed to aerosol performance or device integration may be harder to design around but easier to avoid through engineering.

What commercial opportunities exist beyond generic substitution?

The largest opportunities are platform-based rather than excipient-only products.

Lower-carbon pMDI technology

A propellant-transition platform could support DULERA-like products and other inhaled corticosteroid/LABA combinations. The commercial value would come from reusable device technology, validated filling processes and a regulatory package that can be applied across multiple products.

Excipient and device licensing

Specialty excipient suppliers can license:

• Suspension stabilizers
• Low-deposition valve technologies
• Compatible lubricants
• Moisture-control systems
• Dose-counter assemblies
• Actuator designs that improve lung delivery

Licensing value is highest when the technology improves a measurable product attribute and can be protected by composition, process or device claims.

Contract manufacturing

Many pharmaceutical companies lack internal HFA filling capacity. A contract manufacturer with validated HFA-227ea handling, low-moisture filling and combination-product quality systems can capture demand from generic and emerging inhalation companies.

Differentiated adherence products

DULERA is administered twice daily. A product with a longer dosing interval, digital dose tracking, dose-counting, or improved actuation feedback could compete on adherence rather than price. Such products would require stronger clinical and commercial positioning than a standard generic.

Geographic expansion

The same active combination can support opportunities in the United States, Europe, Canada, Japan and emerging markets, but regulatory and environmental requirements differ. The European Union has more aggressive scrutiny of fluorinated greenhouse gases, while other markets may remain more focused on cost, local manufacturing and device availability.

What revenue exposure does DULERA create for the originator?

DULERA revenue is exposed to three forces:

1. Generic price erosion after successful ANDA entry.
2. Substitution by other inhaled corticosteroid/LABA products.
3. Environmental and device-driven migration away from HFA-227ea systems.

The originator can reduce exposure through authorized generic arrangements, device upgrades, lifecycle reformulation, geographic licensing and portfolio migration to newer inhaled combinations. Generic entrants face a different exposure profile: the product may generate rapid volume after approval, but reimbursement pressure can compress net pricing quickly.

What generic launch scenarios exist for DULERA?

Scenario	Likely commercial effect
First generic enters after patent settlement	Moderate price erosion with limited early competition
Multiple ANDAs launch near the same date	Rapid price compression and pharmacy substitution
Authorized generic launches	Lower market share and margin for independent generics
Patent litigation delays entry	Continued branded pricing but higher legal cost
Alternative-propellant product launches first	Differentiated pricing but greater development expense
Device mismatch limits substitution	Slower uptake despite regulatory approval

The most investable generic strategy is a technically conservative pMDI with a validated device and a clear Paragraph IV or settlement pathway. The most valuable branded strategy is a lower-emission or easier-to-use inhaler that can command a price premium and extend the platform across multiple molecules.

Key Takeaways

• DULERA uses HFA-227ea, ethanol and oleic acid in a pressurized metered-dose inhaler.
• The excipient system is inseparable from the canister, valve and actuator.
• Generic developers should prioritize aerosol-performance matching, not only inactive-ingredient matching.
• The initial regulatory exclusivity period has expired; current entry risk is primarily patent, litigation, device and manufacturing related.
• Paragraph IV exposure depends on the current Orange Book listing and the proposed generic labeling.
• Close-formulation pMDI development offers the lowest regulatory risk.
• Alternative propellants offer the strongest long-term commercial opportunity but require major technical and regulatory investment.
• Device licensing, HFA contract manufacturing and lower-carbon inhaler platforms are attractive adjacent markets.
• The patent estate is likely stronger around specific formulation, device, use and manufacturing claims than around the mature active ingredients individually.

FAQs About DULERA Excipient and Commercial Strategy

Can a generic DULERA product use different excipients?

Yes, but different excipients can change emitted dose, particle-size distribution, plume behavior, stability and valve performance. FDA approval depends on demonstrating pharmaceutical and performance equivalence, not simply matching the active ingredients.

Is HFA-227ea likely to be replaced in future DULERA-type inhalers?

It is a plausible long-term target because of its high global-warming potential. Replacement would require extensive reformulation, device compatibility testing, stability work and regulatory review.

Does oleic acid create a major patent barrier?

Oleic acid itself is a common excipient. The relevant risk is more likely to involve its concentration, combination with the active ingredients, suspension behavior or use within a specific aerosol system.

Would a dry-powder mometasone/formoterol product be a generic DULERA substitute?

Usually not in the same regulatory or commercial sense as an equivalent pMDI. A different inhaler format can require a different regulatory pathway and may not receive automatic pharmacy substitution.

What is the most defensible commercial investment in DULERA-related technology?

A validated inhalation platform combining low-emission propellant compatibility, reliable suspension processing, device performance and scalable HFA manufacturing has broader value than a single excipient patent.

References

1. U.S. Food and Drug Administration. (2024). DULERA (mometasone furoate and formoterol fumarate dihydrate) inhalation aerosol: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
4. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally inhaled and nasal drug products.